MCID: CHL018
MIFTS: 50

Childhood Medulloblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Childhood Medulloblastoma

MalaCards integrated aliases for Childhood Medulloblastoma:

Name: Childhood Medulloblastoma 12 53 15
Medulloblastoma, Childhood 53 73
Pediatric Medulloblastoma 12
Medulloblastoma Childhood 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3869
MeSH 44 D008527
NCIt 50 C3997
UMLS 73 C0278510

Summaries for Childhood Medulloblastoma

MalaCards based summary : Childhood Medulloblastoma, also known as medulloblastoma, childhood, is related to medulloblastoma and basal cell carcinoma, and has symptoms including vomiting, gait ataxia and headache. An important gene associated with Childhood Medulloblastoma is CRNDE (Colorectal Neoplasia Differentially Expressed), and among its related pathways/superpathways are ERK Signaling and Pathways in cancer. The drugs Lomustine and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and liver, and related phenotypes are cardiovascular system and behavior/neurological

Related Diseases for Childhood Medulloblastoma

Diseases related to Childhood Medulloblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 medulloblastoma 29.8 DDX3X ERBB3 ERBB4 MYC MYCN NTRK3
2 basal cell carcinoma 29.4 PTCH1 SUFU TP53
3 vulva basal cell carcinoma 10.2 MYC PTCH1
4 askin's tumor 10.2 MYC MYCN
5 bone ewing's sarcoma 10.1 MYC MYCN
6 nodular medulloblastoma 10.1 PTCH1 SUFU
7 microform holoprosencephaly 10.1 PTCH1 SUFU
8 calcifying epithelial odontogenic tumor 10.0 PTCH1 TP53
9 b cell prolymphocytic leukemia 10.0 MYC TP53
10 megaesophagus 10.0 MYC TP53
11 hypertrichosis universalis congenita, ambras type 10.0 MYC TP53
12 suppressor of tumorigenicity 3 10.0 MYC TP53
13 pleuropulmonary blastoma 10.0 MYCN TP53
14 uterine corpus cancer 10.0 MYC TP53
15 richter's syndrome 10.0 MYC TP53
16 bartholin's gland disease 10.0 ERBB3 TP53
17 ewing's family of tumors 9.9
18 central nervous system benign neoplasm 9.9 MYCN TP53
19 alopecia 9.9
20 cerebral primitive neuroectodermal tumor 9.9 MYC MYCN TP53
21 medullomyoblastoma 9.9 MYC MYCN TP53
22 autonomic nervous system neoplasm 9.9 MYC MYCN TP53
23 peripheral nervous system neoplasm 9.9 MYC MYCN TP53
24 small cell cancer of the lung 9.9 MYC MYCN TP53
25 fallopian tube carcinoma 9.9 MYC TP53
26 cerebellar liponeurocytoma 9.8 PTCH1 SUFU TP53
27 germ cell and embryonal cancer 9.8 MYC TP53
28 keratocystic odontogenic tumor 9.8 PTCH1 SUFU TP53
29 rhabdomyosarcoma 9.8 MYCN PTCH1 TP53
30 juvenile pilocytic astrocytoma 9.8 DDX3X TP53
31 wilms tumor 1 9.8 MYC MYCN TP53
32 nervous system cancer 9.8 MYC MYCN PTCH1 TP53
33 basal cell nevus syndrome 9.8
34 aging 9.8
35 basal cell carcinoma 1 9.8
36 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
37 hypothyroidism 9.8
38 atypical teratoid rhabdoid tumor 9.8
39 rhabdoid cancer 9.8
40 ependymoma 9.8
41 radiation induced cancer 9.8
42 herpes simplex 9.8
43 cytomegalovirus infection 9.8
44 glioblastoma 9.7 ERBB3 MYC MYCN TP53
45 malignant mesenchymoma 9.7 NTRK3 TP53
46 adult medulloblastoma 9.7 MYCN PTCH1 SUFU TP53
47 brain cancer 9.7 MYC MYCN NTRK3 PTCH1 TP53
48 central nervous system cancer 9.6 MYC MYCN PTCH1 SUFU TP53
49 adenocarcinoma 9.6 ERBB3 ERBB4 MYC NTRK3 TP53
50 infratentorial cancer 9.5 MYC MYCN NTRK3 PTCH1 SUFU TP53

Graphical network of the top 20 diseases related to Childhood Medulloblastoma:



Diseases related to Childhood Medulloblastoma

Symptoms & Phenotypes for Childhood Medulloblastoma

UMLS symptoms related to Childhood Medulloblastoma:


vomiting, gait ataxia, headache

MGI Mouse Phenotypes related to Childhood Medulloblastoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.2 DDX3X ERBB3 ERBB4 MYC MYCN NTRK3
2 behavior/neurological MP:0005386 10.16 ERBB3 ERBB4 MYC MYCN NTRK3 PTCH1
3 growth/size/body region MP:0005378 10.15 DDX3X ERBB3 MYC MYCN NTRK3 PTCH1
4 mortality/aging MP:0010768 10.13 DDX3X ERBB3 ERBB4 MYC MYCN NTRK3
5 embryo MP:0005380 10.11 DDX3X ERBB3 ERBB4 MYC MYCN PTCH1
6 nervous system MP:0003631 10.02 DDX3X ERBB3 ERBB4 MYC MYCN NTRK3
7 craniofacial MP:0005382 10.01 ERBB4 MYC MYCN PTCH1 SUFU TP53
8 digestive/alimentary MP:0005381 10 ERBB3 MYC MYCN PTCH1 SUFU TP53
9 integument MP:0010771 9.95 ERBB3 ERBB4 MYC PTCH1 SUFU TP53
10 muscle MP:0005369 9.95 DDX3X ERBB3 ERBB4 MYC MYCN PTCH1
11 limbs/digits/tail MP:0005371 9.85 MYC MYCN PTCH1 SUFU TP53
12 normal MP:0002873 9.85 DDX3X ERBB3 ERBB4 MYC MYCN NTRK3
13 neoplasm MP:0002006 9.77 ERBB3 MYC PTCH1 SUFU TP53
14 no phenotypic analysis MP:0003012 9.73 MYC MYCN NTRK3 PTCH1 SUFU TP53
15 pigmentation MP:0001186 9.35 ERBB3 MYC PTCH1 SUFU TP53
16 respiratory system MP:0005388 9.23 ERBB3 ERBB4 MYCN NTRK3 PTCH1 SH3GL1

Drugs & Therapeutics for Childhood Medulloblastoma

Drugs for Childhood Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
2
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
4
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
5
leucovorin Approved Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
7
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
8
Methotrexate Approved Phase 3,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
9
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
10
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
11
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
12
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
13
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
18
Isotretinoin Approved Phase 3,Phase 1,Not Applicable 4759-48-2 5538 5282379
19
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
20
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
22
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Not Applicable 302-79-4 5538 444795
23
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Not Applicable 11103-57-4, 68-26-8 445354
24 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
25 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
27 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamin B Complex Phase 3,Phase 2,Not Applicable
33 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Not Applicable
36 Antimetabolites Phase 3,Phase 2,Not Applicable
37 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 Folate Phase 3,Phase 2,Not Applicable
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
40 Vitamin B9 Phase 3,Phase 2,Not Applicable
41 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
42 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Liver Extracts Phase 3,Phase 2,Phase 1
44 Vitamins Phase 3,Not Applicable
45 Calcium, Dietary Phase 3,Phase 2
46 Trace Elements Phase 3,Phase 2
47 Antidotes Phase 3,Phase 2,Phase 1
48 Micronutrients Phase 3,Phase 2
49 sodium thiosulfate Phase 3,Phase 1,Phase 2
50 Anti-Infective Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 132)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
2 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
3 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed NCT00085735 Phase 3 Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate
4 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
5 Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
6 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
7 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
8 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
9 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
10 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
11 Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma Suspended NCT00392327 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Isotretinoin;Vincristine Sulfate
12 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
13 Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery Unknown status NCT00276666 Phase 2 cisplatin;lomustine;vincristine sulfate
14 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
15 Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma Completed NCT02017964 Phase 2 Vincristine Sulfate;Cyclophosphamide;Methotrexate;Etoposide;Carboplatin
16 Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Completed NCT01239316 Phase 2 Vismodegib
17 Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma Completed NCT00003573 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
18 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Completed NCT00003211 Phase 2 amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate
19 Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors Completed NCT00025077 Phase 2 carboplatin;cyclophosphamide;thiotepa
20 Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors Completed NCT00002594 Phase 2 cyclophosphamide;melphalan
21 Ga-DOTATOC Versus Octreoscan + CT Completed NCT01869725 Phase 2
22 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
23 Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors Completed NCT00003203 Phase 2 carboplatin;cisplatin;cyclophosphamide;vincristine sulfate
24 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
25 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
26 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
27 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
28 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
29 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Completed NCT00005811 Phase 2 topotecan hydrochloride
30 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
31 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
32 Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
33 Lobradimil and Carboplatin in Treating Children With Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
34 Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00003241 Phase 2 phenylacetate
35 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
36 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
37 Docetaxel in Treating Children With Recurrent Solid Tumors Completed NCT00002825 Phase 2 docetaxel
38 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
39 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
40 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
41 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
42 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
43 Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Recruiting NCT02724579 Phase 2 Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate
44 Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Recruiting NCT02684071 Phase 2 Intra thecal methotrexate;topotecan;cyclophosphamide
45 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib
46 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
47 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
48 A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Recruiting NCT01878617 Phase 2 Cyclophosphamide;Cisplatin;Vincristine;Vismodegib;Pemetrexed;Gemcitabine
49 Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Recruiting NCT02624388 Phase 2 Genistein;Placebo
50 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Active, not recruiting NCT01217437 Phase 2 Irinotecan Hydrochloride;Temozolomide

Search NIH Clinical Center for Childhood Medulloblastoma

Genetic Tests for Childhood Medulloblastoma

Anatomical Context for Childhood Medulloblastoma

MalaCards organs/tissues related to Childhood Medulloblastoma:

41
Brain, Bone, Liver, Bone Marrow, Lung, Cervix, B Cells

Publications for Childhood Medulloblastoma

Articles related to Childhood Medulloblastoma:

(show top 50) (show all 129)
# Title Authors Year
1
Neuropsychological consequences of childhood medulloblastoma and possible interventions: A review. ( 29716738 )
2018
2
Study on Contribution of Biological Interpretable and Computer-Aided Features Towards the Classification of Childhood Medulloblastoma Cells. ( 29974336 )
2018
3
National cancer registry and broad institutional cooperation: turning points in treating childhood medulloblastoma in Iran. ( 29804211 )
2018
4
Intellectual, educational, and situation-based social outcome in adult survivors of childhood medulloblastoma. ( 29336639 )
2018
5
Childhood Medulloblastoma Revisited. ( 30516696 )
2018
6
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. ( 28545823 )
2017
7
Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. ( 29189165 )
2017
8
Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia. ( 28717752 )
2017
9
Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ( 27900530 )
2017
10
Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. ( 28039368 )
2016
11
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. ( 27040285 )
2016
12
Childhood medulloblastoma. ( 27375228 )
2016
13
Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns. ( 27770281 )
2016
14
The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ( 27785591 )
2016
15
Evolving molecular era of childhood medulloblastoma: time to revisit therapy. ( 26617331 )
2016
16
Evidence of high mortality in long term survivors of childhood medulloblastoma. ( 25557108 )
2015
17
The use of 5-ALA to assist complete removal of residual non-enhancing part of childhood medulloblastoma: a case report. ( 26070965 )
2015
18
Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature. ( 24276042 )
2014
19
The biologic era of childhood medulloblastoma and clues to novel therapies. ( 24754593 )
2014
20
NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. ( 24708907 )
2014
21
Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. ( 25346052 )
2014
22
Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. ( 24569911 )
2014
23
Germline Mutations in SUFU Cause Gorlin Syndrome-Associated Childhood Medulloblastoma and Redefine the Risk Associated With PTCH1 Mutations. ( 25403219 )
2014
24
miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. ( 23970061 )
2013
25
A contemporary review of molecular candidates for the development and treatment of childhood medulloblastoma. ( 23292496 )
2013
26
Treatment options for childhood medulloblastoma. ( 24069828 )
2013
27
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. ( 22153558 )
2012
28
Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. ( 22994552 )
2012
29
Identification of suitable endogenous control genes for microRNA expression profiling of childhood medulloblastoma and human neural stem cells. ( 22980291 )
2012
30
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. ( 22139329 )
2012
31
Cerebral white matter integrity and executive function in adult survivors of childhood medulloblastoma. ( 23095827 )
2012
32
An exploratory case-only analysis of gene-hazardous air pollutant interactions and the risk of childhood medulloblastoma. ( 22389292 )
2012
33
Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma. ( 22350379 )
2012
34
Low-grade bone lesions in survivors of childhood medulloblastoma/primitive neuroectodermal tumor. ( 22054800 )
2012
35
Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile. ( 22826514 )
2012
36
Chemotherapy dose-intensity and survival for childhood medulloblastoma. ( 22993333 )
2012
37
Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. ( 20931205 )
2011
38
Early traits of metabolic syndrome in pediatric post-cancer survivors: outcomes in adolescents and young adults treated for childhood medulloblastoma. ( 22218450 )
2011
39
Risk-adapted chemotherapy in childhood medulloblastoma. ( 21554052 )
2011
40
Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells. ( 21931624 )
2011
41
Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. ( 21367970 )
2011
42
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. ( 20845476 )
2011
43
Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. ( 21317922 )
2011
44
Intact language skills and semantic processing speed following the use of fractionated cranial irradiation therapy for the treatment of childhood medulloblastoma: a 4-year follow-up study. ( 21207315 )
2011
45
Expression of Oa8P-methylguanine-DNA methyltransferase in childhood medulloblastoma. ( 20820873 )
2011
46
Recurrence in childhood medulloblastoma. ( 21069427 )
2011
47
Childhood medulloblastoma. ( 21129995 )
2011
48
Progress in sequencing human cancer genomes: advancements in childhood medulloblastoma. ( 21900800 )
2011
49
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. ( 20921458 )
2011
50
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. ( 20940197 )
2010

Variations for Childhood Medulloblastoma

Expression for Childhood Medulloblastoma

Search GEO for disease gene expression data for Childhood Medulloblastoma.

Pathways for Childhood Medulloblastoma

Pathways related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 ERBB3 ERBB4 MYC NTRK3 PTCH1 SUFU
2 12.58 MYC PTCH1 SUFU TP53
3 12.48 ERBB3 ERBB4 MYC TP53
4
Show member pathways
12.26 ERBB3 ERBB4 MYC TP53
5
Show member pathways
12.2 ERBB3 ERBB4 MYC TP53
6
Show member pathways
12.16 ERBB3 ERBB4 NTRK3 TP53
7 12.02 MYC MYCN TP53
8
Show member pathways
11.88 PTCH1 SUFU TP53
9
Show member pathways
11.76 ERBB3 ERBB4 TP53
10
Show member pathways
11.74 ERBB3 ERBB4 MYC NTRK3 TP53
11 11.66 ERBB3 ERBB4 MYC PTCH1 TP53
12 11.4 MYC MYCN TP53
13 11.36 MYC NTRK3 TP53
14 11.18 ERBB3 ERBB4 MYC NTRK3 TP53
15 11.11 MYC TP53
16 11.09 ERBB3 ERBB4 NTRK3
17 11.03 MYC TP53
18 10.89 MYC TP53
19
Show member pathways
10.88 MYC TP53
20 10.02 MYC MYCN

GO Terms for Childhood Medulloblastoma

Cellular components related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basal plasma membrane GO:0009925 8.96 ERBB3 ERBB4
2 receptor complex GO:0043235 8.8 ERBB3 ERBB4 NTRK3

Biological processes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.75 ERBB3 ERBB4 MYC
2 peptidyl-tyrosine phosphorylation GO:0018108 9.69 ERBB3 ERBB4 NTRK3
3 positive regulation of MAPK cascade GO:0043410 9.65 ERBB3 ERBB4 NTRK3
4 positive regulation of transcription, DNA-templated GO:0045893 9.65 ERBB4 MYC MYCN PTCH1 TP53
5 negative regulation of signal transduction GO:0009968 9.63 ERBB3 ERBB4 NTRK3
6 liver regeneration GO:0097421 9.58 MYC PTCH1
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.58 ERBB3 ERBB4 NTRK3
8 negative regulation of fibroblast proliferation GO:0048147 9.57 MYC TP53
9 intrinsic apoptotic signaling pathway GO:0097193 9.56 DDX3X TP53
10 ERBB2 signaling pathway GO:0038128 9.55 ERBB3 ERBB4
11 regulation of cell motility GO:2000145 9.54 ERBB3 ERBB4
12 response to gamma radiation GO:0010332 9.52 MYC TP53
13 negative regulation of smoothened signaling pathway GO:0045879 9.49 PTCH1 SUFU
14 mammary gland epithelial cell differentiation GO:0060644 9.43 ERBB4 PTCH1
15 negative regulation of apoptotic process GO:0043066 9.43 DDX3X ERBB3 ERBB4 MYC NTRK3 TP53
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.37 MYCN TP53
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.33 ERBB3 ERBB4 NTRK3
18 negative regulation of cell division GO:0051782 9.32 MYC PTCH1
19 positive regulation of gene expression GO:0010628 9.1 DDX3X ERBB3 MYC MYCN NTRK3 TP53

Molecular functions related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.43 ERBB3 ERBB4 NTRK3
2 protein tyrosine kinase activity GO:0004713 9.33 ERBB3 ERBB4 NTRK3
3 transcription factor binding GO:0008134 9.26 DDX3X MYC SUFU TP53
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 ERBB3 ERBB4 NTRK3

Sources for Childhood Medulloblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....